Please Wait.....
Report
Amgen, Inc. (AMGN:NASD) Strategic SWOT, PESTLE, Value Chain Analysis and Financial Insight - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends
Company Report I 2024-02-01 I 114 Pages I Quaintel Research
Report Summary
Amgen, Inc. (AMGN:NASD) Strategic SWOT, PESTLE, Value Chain Analysis and Financial Insight - A 360 Review of Opportunities, Challenges and Risk, Corporate and ESG Strategies, Competitive Intelligence, Financial and Operational KPI's, and Recent Trends Report is a comprehensive and easily accessible overview of Amgen, Inc.'s business operations. It provides a detailed analysis of the company's financial and strategic standing, as well as its position in the industry compared to competitors. The report includes several key features to facilitate decision-making and provide insights into the company's performance.
The report begins with in-depth information about Amgen, Inc. including key insights, business segments, key executives, locations, products and services, historical events, corporate strategy, and management discussions. This section provides a solid foundation for understanding the company's key attributes.
Next, the report assesses Amgen, Inc.'s strategic standing through various analyses. The ESG spotlight evaluates the company's environmental, social, and governance performance, providing insights into its sustainability efforts and ethical practices. The SWOT analysis examines the company's internal strengths and weaknesses, as well as external opportunities and threats. The PESTLE analysis evaluates the external factors impacting the company's operations and market environment. Additionally, the value chain analysis identifies value-adding activities and areas for operational optimization. By integrating these strategic analyses, the report offers a comprehensive understanding of Amgen, Inc.'s overall strategic standing and supports informed decision-making and strategic planning.
The report also covers Amgen, Inc.'s financial analysis basis of latest income statement, balance sheet, and cash flow statement. Key financial ratios related to profitability, asset turnover, credit, market, and long-term solvency are outlined, providing guidance for investment decisions. Furthermore, the report compares Amgen, Inc.'s financial parameters with those of its competitors, offering a unique analysis of the competitive landscape. This information helps manage the business environment and improve sales activities by gaining insight into competitors' operations.
Finally, the report includes recent news and deal activities undertaken by Amgen, Inc. enhancing awareness of the company's business trends, growth perspectives, and more.
Key Highlights
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on areas such as inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience. Amgen Inc. operates in two main business segments: human therapeutics and biosimilars. The human therapeutics segment focuses on treating conditions such as cancer, inflammation, bone health, cardiovascular disease, and nephrology. The biosimilars segment develops and commercializes biosimilar versions of innovator biologics. Amgen Inc. offers a range of therapeutics to treat conditions such as plaque psoriasis, rheumatoid arthritis, anemia, multiple myeloma, osteoporosis, and more. Some of its key products include Enbrel, Neulasta, Prolia, Xgeva, Otezla, Aranesp, and Kyprolis. It also markets drugs like Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, and Sensipar. Founded in 1980, the company is headquartered in Thousand Oaks, California, United States.
Amgen, Inc. in the News:-
- 03-Aug-2023 - Amgen reports second quarter financial results
- 19-Apr-2023 - Amgen wins patent appeal on otezla (apremilast)
- 31-Jan-2023 - Amjevita (adalimumab-atto), first biosimilar to humira, now available in the united states
- 06-Jan-2023 - Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at asco 2023
- 04-Jan-2023 - Amgen to present at the 41st annual j.P. Morgan healthcare conference
Scope
- Tactical Analysis:- Various strategic frameworks to gain insights into a company's competitive position and operational environment. These analytical tools assist in identifying competitive advantages, potential risks, and areas for improvement and efficiency, enabling companies to make informed tactical decisions.
- Business Strategy:- Contributes to shaping the company's overall direction, goals, and decision-making processes, ensuring long-term success and alignment with stakeholder expectations.
- Financial Position:- Provide valuable information on the financial performance and investor sentiment surrounding the company. Indicating the level of confidence and expectations in the company's future prospects. These components collectively contribute to understanding the financial health and market perception of the company.
- Company Fundamentals:- These fundamentals offer valuable insights into the company's history, operations, leadership, and geographical presence, aiding in a comprehensive understanding of the organization.
- Competitive Landscape:- An identification of the company's main competitors, providing insights into the competitive landscape it operates in.
Reasons to Buy
- Comprehensive Understanding of the Amgen, Inc.'s internal and external factors through SWOT analysis, PESTLE analysis, Value Chain analysis, Financial Analysis, and Competitors Benchmarking.
- Strive Strategic Decision Making with various analyses and identifying potential customers and suppliers.
- Mitigate Risk with help of thorough analysis of internal and external factors. Furthermore, develop strategies and contingency plans to address these challenges and minimize their impact on business operations.
- Competitive Benchmarking will help to gain a competitive advantage by understanding industry trends, customer preferences, and best practices.
- Financial Performance Evaluation provides crucial insights into key financial ratios and trends, supporting better financial decision-making and resource allocation.
- Valuable insights from the report enable investors and partners to make informed decisions regarding potential Collaborations, Investments, or Partnerships with the company.
Additionally, available deep-dive analysis on the company Amgen, Inc.:
- Amgen, Inc. Porter's Five Forces Analysis
- Amgen, Inc. VRIO Analysis
- Amgen, Inc. BCG Analysis
- Amgen, Inc. Segmentation, Targeting and Positioning (STP) Analysis
- Amgen, Inc. Ansoff Matrix Analysis
Table of Contents
COMPANY EXECUTIVE SUMMARY
Table of Contents
Tables
Charts
Amgen, Inc. - Key Company Facts
Amgen, Inc. - Company Description
Amgen, Inc. - Top Executives
Amgen, Inc. - Top Executives Biographies
Amgen, Inc. - Head Office & Locations
Head Office - Country
Key Subsidiaries
Key Joint Ventures
Amgen, Inc. - Products and Services
Products
Amgen, Inc. - Historic Events
Amgen, Inc. - Company's Management Discussion
Amgen, Inc. - Company's Mission and Vision
Mission
Amgen, Inc. - Corporate Strategy
Amgen, Inc. - Business Description
Therapeutic Focus Areas
Product Portfolio
Global Distribution Network
Collaborative Ventures
Research and Development (R&D)
Amgen, Inc. - ESG Spotlight
Environment
Social
Corporate Governance
Amgen, Inc. - SWOT Analysis
Overview
Strengths
Weaknesses
Opportunities
Threats
Amgen, Inc. - PESTLE Analysis
Overview
Political Factors
Economic Factors
Social Factors
Technological Factors
Legal Factors
Environmental Factors
Amgen, Inc. - Value Chain Analysis
Overview
Primary Activities
Inbound Logistics
Operations
Outbound Logistics
Marketing and Sales
Service
Support Activities
Procurement
Technology
Human Resource
Firm Infrastructure
Amgen, Inc. - Financial Deep Dive
Share Price Trend - Jan-2023 to Jan-2024 (Average Share Closing Price)
Profit and Loss Statement
Summary of Profit and Loss Statement
Balance Sheet
Summary of Balance Sheet
Cash Flow Statement
Summary of Cash Flow Statement
Key Financial Ratio Analysis
Amgen, Inc. - Ratio Charts
Activity Ratio Charts
Growth Ratios Charts
Leverage Ratio Charts
Liquidity Ratio Charts
Profitability Ratio Charts
Competing Players
Snapshot of Competing Players
Bristol-Myers Squibb Co
Key Company Facts
Company Description
Gilead Sciences Inc.
Key Company Facts
Company Description
Regeneron Pharmaceuticals Inc
Key Company Facts
Company Description
Vertex Pharmaceuticals Incorporated
Key Company Facts
Company Description
Zoetis Inc
Key Company Facts
Company Description
Amgen, Inc. - Key Deals
06-Oct-2023 - Amgen completes acquisition of horizon therapeutics plc
09-May-2023 - Amgen and TScan Therapeutics announce collaboration to identify novel targets in crohn's disease
12-Dec-2022 - Amgen agrees to acquire horizon therapeutics for $27.8 billion
20-Oct-2022 - Amgen successfully completes acquisition of chemocentryx
27-Jul-2021 - Amgen to acquire privately held teneobio for $900 million in cash with future contingent milestone payments
16-Apr-2021 - Amgen successfully completes acquisition of five prime therapeutics
Amgen, Inc. - In the News
14-Dec-2023 - Amgen announces executive appointments to accelerate innovation
07-Nov-2023 - Amgen presents new research in early psoriatic arthritis at acr 2023
20-Oct-2023 - Amgen presents new tarlatamab data in small cell lung cancer
20-Sep-2023 - Amgen launches partners of choice network of eight leading oncology academic centers
03-Aug-2023 - Amgen reports second quarter financial results
19-Apr-2023 - Amgen wins patent appeal on otezla (apremilast)
31-Jan-2023 - Amjevita (adalimumab-atto), first biosimilar to humira, now available in the united states
06-Jan-2023 - Amgen presents new scientific and clinical research across its diverse oncology portfolio and pipeline at asco 2023
04-Jan-2023 - Amgen to present at the 41st annual j.P. Morgan healthcare conference
03-Aug-2022 - Amgen appoints michael v. Drake to board of directors
26-May-2022 - New data showcases how amgen is advancing all angles of cancer care through innovative oncology portfolio and pipeline at asco 2022
07-Mar-2022 - Global biotechnology leader amgen breaks ground on new manufacturing facility in north carolina
22-Feb-2022 - Amgen issues inaugural green bond to advance esg goals
Appendix
Definitions
SWOT Analysis
PESTLE Analysis
Value Chain Analysis
ESG Spotlight
Financial Deep Dive
Financial Ratios -
Activity Ratios
Growth Ratios
Leverage Ratios
Liquidity Ratios
Market Ratios
Profitability Ratios
Research Methodology
Disclaimer
Contact Us
Tables
Table 1: Amgen, Inc. - Company Facts
Table 2: Amgen, Inc. - Top Executives
Table 3: Amgen, Inc. - Top Executives Biographies
Table 4: Amgen, Inc. - Subsidiaries
Table 5: Amgen, Inc. - Key Joint Ventures
Table 6: Amgen, Inc. - Products
Table 7: Amgen, Inc. - Historic Events
Table 8: Amgen, Inc. - Share Price Trend - Jan-2023 to Jan-2024
Table 9: Amgen, Inc. - Ratio Analysis - 2019-2022
Table 10: Amgen, Inc. - Competing Players
Table 11: Competing Players - Bristol-Myers Squibb Co - Key Company Facts
Table 12: Competing Players - Bristol-Myers Squibb Co - Key Financials
Table 13: Competing Players - Gilead Sciences Inc. - Key Company Facts
Table 14: Competing Players - Gilead Sciences Inc. - Key Financials
Table 15: Competing Players - Regeneron Pharmaceuticals Inc - Key Company Facts
Table 16: Competing Players - Regeneron Pharmaceuticals Inc - Key Financials
Table 17: Competing Players - Vertex Pharmaceuticals Incorporated - Key Company Facts
Table 18: Competing Players - Vertex Pharmaceuticals Incorporated - Key Financials
Table 19: Competing Players - Zoetis Inc - Key Company Facts
Table 20: Competing Players - Zoetis Inc - Key Financials
Charts
Figure 1: Amgen, Inc. - SWOT Analysis
Figure 2: Amgen, Inc. - PESTLE Analysis
Figure 3: Amgen, Inc. - Value Chain Analysis
Figure 4: Amgen, Inc. - Average Share Price Trend - Jan-2023 to Jan-2024
Figure 5: Amgen, Inc. - Profit and Loss Statement - 2019-2022
Figure 6: Amgen, Inc. - Balance Sheet - 2019-2022
Figure 7: Amgen, Inc. - Cash Flow Statement 2019-2022
Figure 8: Amgen, Inc. - Activity Ratio Charts
Figure 9: Amgen, Inc. - Growth Ratio Charts (Value %)
Figure 10: Amgen, Inc. - Leverage Ratio Charts
Figure 11: Amgen, Inc. - Liquidity Ratio Charts
Figure 12: Amgen, Inc. - Profitability Ratio Charts (Value %)
Figure 13: Competing Players - Bristol-Myers Squibb Co - Key Financials
Figure 14: Competing Players - Gilead Sciences Inc. - Key Financials
Figure 15: Competing Players - Regeneron Pharmaceuticals Inc - Key Financials
Figure 16: Competing Players - Vertex Pharmaceuticals Incorporated - Key Financials
Figure 17: Competing Players - Zoetis Inc - Key Financials
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security